PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
16844679-4	2006	We hypothesized that Marimastat, a broad-spectrum MMP and TNF-alpha converting enzyme (TACE) inhibitor, might modulate this injury through interruption of inflammatory pathways.	marimastat	21-31	a disintegrin and metallopeptidase domain 17	Mus musculus	58-85	
20593020-4	2010	We hypothesized that treatment with a broad-spectrum MMP and TACE-inhibitor (Marimastat) would ameliorate injury and inflammation, leading to decreased fibrogenesis during repeated hepatotoxin-induced liver injury.	marimastat	77-87	a disintegrin and metallopeptidase domain 17	Mus musculus	61-65	
21980496-3	2011	We hypothesized that treatment with the pharmacologic tumor necrosis factor-alpha converting enzyme (TACE)-inhibitor Marimastat would reverse established steatosis, leading to improved outcome following hepatectomy.	marimastat	117-127	a disintegrin and metallopeptidase domain 17	Mus musculus	54-99	
21980496-3	2011	We hypothesized that treatment with the pharmacologic tumor necrosis factor-alpha converting enzyme (TACE)-inhibitor Marimastat would reverse established steatosis, leading to improved outcome following hepatectomy.	marimastat	117-127	a disintegrin and metallopeptidase domain 17	Mus musculus	101-105	
21980496-12	2011	CONCLUSION/SIGNIFICANCE: Treatment with the TACE-inhibitor Marimastat improved surrogate markers for insulin sensitivity and reversed steatosis in mouse models of diet-induced obesity and leptin deficiency, thereby attenuating post-operative injury following hepatectomy.	marimastat	59-69	a disintegrin and metallopeptidase domain 17	Mus musculus	44-48	
16844679-4	2006	We hypothesized that Marimastat, a broad-spectrum MMP and TNF-alpha converting enzyme (TACE) inhibitor, might modulate this injury through interruption of inflammatory pathways.	marimastat	21-31	a disintegrin and metallopeptidase domain 17	Mus musculus	87-91